Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mbf Therapeutics Inc. manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is handled by 1 distinct examiner and 1 distinct art unit, centralizing the company's current prosecution efforts. This concentration suggests that the company is focusing its resources on a specific therapeutic or biological innovation. The pending office action represents the current state of the company's efforts to secure patent protection in this field.
The busiest examiner for the company is QIAN, CELINE X, who is assigned 1 busiest examiner pending office action. The progress of the company's active docket depends on the specific review and guidance provided by this examiner. For a practitioner, it is important to tailor arguments to the specific preferences of this official within the Biotechnology & Pharmaceuticals art unit. The outcome of the 1 pending office action will determine the company's immediate success in expanding its patent portfolio. Navigating the requirements of this individual examiner is the most critical task for the company's current prosecution strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| QIAN, CELINE X | 1 | 47.5% | +17.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18064219 | ENHANCED IMMUNOGENIC DNA/RNA COMPOSITIONS AND METHODS | QIAN, CELINE X | 22d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18064219 | ENHANCED IMMUNOGENIC DNA/RNA COMPOSITIONS AND METHODS | QIAN, CELINE X | 22d overdue |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18064219 | ENHANCED IMMUNOGENIC DNA/RNA COMPOSITIONS AND METHODS | QIAN, CELINE X | 1637 | §103§112 | Final Rejection | 22d overdue | Pending | Dec 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMbf Therapeutics Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Celine X Qian has the most, with 1 of Mbf Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.